SMSally Morrison-Griffiths

Sally Morrison-Griffiths

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sally Morrison-Griffiths has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Reporting of adverse drug reactions by nurses

    by Sally Morrison-Griffiths, Thomas J Walley, B Kevin Park, Alasdair M Breckenridge, Munir Pirmohamed


    • 1 February 2000
      • Vol. 15  (5) , 300-4

    Specialist nurse reporting of adverse drug reactions.

    by S Morrison-Griffiths, M Pirmohamed

    Up to 36% of inpatients experience an adverse drug reaction (ADR) while in hospital. Nurses are well-placed to monitor patients' responses to drugs. Spontaneous reporting of ADRs is the cornerstone of drug safety monitoring and should be the shared responsibility of all health-care staff.


  • Open Access

    Haemolytic anaemia associated with indinavir

    by Sally Morrison-Griffiths, Mark Newman, Colm O'Mahony, Munir Pirmohamed

    Treatment for HIV infection is advancing rapidly. Many new drugs are becoming available and the life expectancy of diagnosed HIV patients has improved dramatically since the introduction of combination antiretroviral therapy. Protease inhibitors have been introduced recently; saquinavir, ritonavir, indinavir, and nelfinavir are currently available in the UK, and there are several new compounds entering the late phases of drug development. Their efficacy has been established,1 2 although less is known about their toxicity, particularly when used long-term. We report a case of severe haemolysis occurring after the initiation of indinavir therapy. Figure Changes in haemoglobin level in relation to drug therapy A 20-year-old man who was first diagnosed as being HIV positive in 1989 was referred to the Genitourinary Medicine Clinic in February 1994 with fatigue and oral candidiasis. He was treated with fluconazole. His CD4 count at the time was 310 cells/mm3. Over the next two years, the CD4 count showed a progressive decrease to below 200 cells/mm3. He refused antiretroviral therapy and prophylaxis for opportunistic infections. In June 1996, the patient was admitted with Pneumocystis carinii pneumonia (PCP) and labial herpes simplex which were treated with prednisolone, famciclovir and high-dose intravenous co-trimoxazole. He responded to the treatment and was discharged in July on PCP prophylaxis (co-trimoxazole 960 mg three times weekly). Antiretroviral therapy was again refused by the patient. The CD4+ count at the time of discharge was 77 cells/mm3, and the haemoglobin level ranged from 8.7 to 10.8 g/dl over the next 3 months. In November 1996, the patient was again admitted to hospital unwell, lethargic and anorexic. He was on oral co-trimoxazole, fluconazole, valaciclovir, and stanozolol. The haemoglobin was 10.7 g/dl (see figure) and CD4+ count was <10 cells/mm3. At this time, the patient agreed …


    • 15 September 1998
      • Vol. 94  (10) , 52-4

    Reporting of adverse drug reactions: practice in the UK.

    by S Morrison-Griffiths, M Pirmohamed, T Walley

    As the range of available drugs becomes increasingly wide, it is ever more important for adverse drug reactions and interactions to be reported. With the extended role of the nurse moving closer towards nurse prescribing, this article seeks to demystify the adverse drug reactions reporting system in the UK, and explain the role of nurses.